These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 33753329)

  • 1. A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.
    Pene Dumitrescu T; Joshi SR; Xu J; Zhan J; Johnson M; Butcher L; Zimmerman E; Webster L; Davidson AM; Lataillade M; Min S
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33753329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I evaluation of pharmacokinetics and tolerability of the HIV-1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults.
    Pene Dumitrescu T; Joshi SR; Xu J; Greene TJ; Johnson M; Butcher L; Zimmerman E; Webster L; Pham TT; Lataillade M; Min S
    Br J Clin Pharmacol; 2021 Sep; 87(9):3501-3507. PubMed ID: 33533507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide in Healthy Japanese Subjects.
    Yamada H; Yonemura T; Nemoto T; Ninomiya N; Irie S
    Clin Pharmacol Drug Dev; 2019 May; 8(4):511-520. PubMed ID: 30325567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers.
    Bevers LAH; Kamphuis AEM; van der Wekken-Pas LCW; Leisegang R; Burger DM; Colbers A
    Clin Pharmacokinet; 2024 May; 63(5):721-728. PubMed ID: 38573477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
    Yager J; Castillo-Mancilla J; Ibrahim ME; Brooks KM; McHugh C; Morrow M; McCallister S; Bushman LR; MaWhinney S; Kiser JJ; Anderson PL
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):323-330. PubMed ID: 32539288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis.
    Massih SA; Atta MG; Thio CL; Tornheim JA; Fuchs EJ; Bakshi RP; Marzinke MA; Hendrix CW; Weld ED
    AIDS Res Ther; 2024 May; 21(1):34. PubMed ID: 38773606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
    Hodder S; Squires K; Kityo C; Hagins D; Avihingsanon A; Kido A; Jiang S; Kulkarni R; Cheng A; Cao H
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):209-213. PubMed ID: 29481486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
    Gaur AH; Kizito H; Prasitsueubsai W; Rakhmanina N; Rassool M; Chakraborty R; Batra J; Kosalaraksa P; Luesomboon W; Porter D; Shao Y; Myers M; Ting L; SenGupta D; Quirk E; Rhee MS
    Lancet HIV; 2016 Dec; 3(12):e561-e568. PubMed ID: 27765666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
    Crauwels HM; Baugh B; Van Landuyt E; Vanveggel S; Hijzen A; Opsomer M
    Clin Pharmacol Drug Dev; 2019 May; 8(4):480-491. PubMed ID: 30412360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed pregnant women with HIV.
    Zhang H; Hindman JT; Lin L; Davis M; Shang J; Xiao D; Avihingsanon A; Arora P; Palaparthy R; Girish S; Marathe DD
    AIDS; 2024 Jan; 38(1):F1-F9. PubMed ID: 37939141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies).
    Ackaert O; McDougall D; Pérez-Ruixo C; Pérez-Ruixo JJ; Jezorwski J; Crauwels HM
    AAPS J; 2021 Jun; 23(4):82. PubMed ID: 34100149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial.
    Gaur AH; Cotton MF; Rodriguez CA; McGrath EJ; Helström E; Liberty A; Natukunda E; Kosalaraksa P; Chokephaibulkit K; Maxwell H; Wong P; Porter D; Majeed S; Yue MS; Graham H; Martin H; Brainard DM; Pikora C
    Lancet Child Adolesc Health; 2021 Sep; 5(9):642-651. PubMed ID: 34302760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EVG/COBI/FTC/TAF Bioequivalence Comparing Whole Tablets with Tablets Dissolved in Tap Water.
    Andrade A; Fuchs EJ; Marzinke MA; Abdul Massih S; Breakey J; Beselman S; McNicholl I; Hendrix CW
    AIDS Res Hum Retroviruses; 2023 Jan; 39(1):38-43. PubMed ID: 36301928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study.
    Hocqueloux L; Lefeuvre S; Bois J; Brucato S; Alix A; Valentin C; Peyro-Saint-Paul L; Got L; Fournel F; Dargere S; Prazuck T; Fournier A; Gregoire N; McNicholl I; Parienti JJ
    J Antimicrob Chemother; 2022 Dec; 78(1):161-168. PubMed ID: 36322475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steady-state pharmacokinetics of plasma tenofovir alafenamide (TAF), tenofovir (TFV) and emtricitabine (FTC), and intracellular TFV-diphosphate and FTC-triphosphate in HIV-1 infected old Japanese patients treated with bictegravir/FTC/TAF.
    Tran HT; Tsuchiya K; Kawashima A; Watanabe K; Hayashi Y; Ryu S; Hamada A; Gatanaga H; Oka S
    Glob Health Med; 2023 Aug; 5(4):216-222. PubMed ID: 37655187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF).
    Coyle RP; Morrow M; Mann SC; Mainella V; Ellis SL; Schwab S; Coppinger C; Barker N; Ellison L; Zheng JH; Al Zuabi S; Alpert PE; Carnes TC; Buffkin DE; Chai PR; Bushman LR; Kiser JJ; MaWhinney S; Brooks KM; Anderson PL; Castillo-Mancilla JR
    Clin Infect Dis; 2024 Apr; ():. PubMed ID: 38636950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature.
    Rowe SM; Clary JC; Drummond M; Derrick C; Sanasi K; Bookstaver PB
    Am J Health Syst Pharm; 2022 Aug; 79(16):1330-1336. PubMed ID: 35511892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
    Massud I; Cong ME; Ruone S; Holder A; Dinh C; Nishiura K; Khalil G; Pan Y; Lipscomb J; Johnson R; Deyounks F; Rooney JF; Babusis D; Park Y; McCallister S; Callebaut C; Heneine W; García-Lerma JG
    J Infect Dis; 2019 Oct; 220(11):1826-1833. PubMed ID: 31362305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial.
    Thurman AR; Schwartz JL; Cottrell ML; Brache V; Chen BA; Cochón L; Ju S; McGowan I; Rooney JF; McCallister S; Doncel GF
    EClinicalMedicine; 2021 Jun; 36():100893. PubMed ID: 34041459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
    DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.